UPDATE: RBC Capital Starts Gemphire Therapeutics (GEMP) at Outperform
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
(Updated - August 30, 2016 7:41 AM EDT)
RBC Capital initiated coverage on Gemphire Therapeutics (NASDAQ: GEMP) with an Outperform rating and a price target of $25. Analyst Adnan Butt sees potential for significant upside.
"We initiate coverage with an Outperform rating and $25 price target. Gemcabene is differentiated and lowers both cholesterol and triglyceride levels to address cardiovascular diseases affecting 16M patients in the U.S. alone. Phase 2b trials are ongoing and could have data in 2017. GEMP has development flexibility, multiple paths to maximize gemcabene opportunity, owns all rights, and there is scarcity value for cardiovascular assets," said Butt.
Shares of Gemphire Therapeutics closed at $10.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Seaport Global Securities Starts Union Pacific (UNP) at Buy
- RBC Capital Raises Price Target on Benchmark Electronics (BHE) Following In-Line 3Q
- H.C. Wainwright Downgrades Vertex (VRTX) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!